KR20210096121A - 님 추출물의 항당뇨 활성 및 유로리틴 a 및 b의 상승작용적 조합물 - Google Patents

님 추출물의 항당뇨 활성 및 유로리틴 a 및 b의 상승작용적 조합물 Download PDF

Info

Publication number
KR20210096121A
KR20210096121A KR1020217017005A KR20217017005A KR20210096121A KR 20210096121 A KR20210096121 A KR 20210096121A KR 1020217017005 A KR1020217017005 A KR 1020217017005A KR 20217017005 A KR20217017005 A KR 20217017005A KR 20210096121 A KR20210096121 A KR 20210096121A
Authority
KR
South Korea
Prior art keywords
aqueous extract
azadirachta indica
weeks
levels
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217017005A
Other languages
English (en)
Korean (ko)
Inventor
무루가난담 에이. 비라라가반
찬단 케이. 센
산야시 알. 칼리딘디
Original Assignee
나트레온 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나트레온 인코퍼레이티드 filed Critical 나트레온 인코퍼레이티드
Publication of KR20210096121A publication Critical patent/KR20210096121A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217017005A 2018-11-05 2019-11-05 님 추출물의 항당뇨 활성 및 유로리틴 a 및 b의 상승작용적 조합물 Ceased KR20210096121A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201841041788 2018-11-05
IN201841041788 2018-11-05
US16/672,743 2019-11-04
US16/672,743 US20200138892A1 (en) 2018-11-05 2019-11-04 Anti-diabetic activity of neem extract and synergistic combinations of urolithins a and b
PCT/US2019/059774 WO2020097014A1 (en) 2018-11-05 2019-11-05 Anti-diabetic activity of neem extract and synergistic combinations of urolithins a and b

Publications (1)

Publication Number Publication Date
KR20210096121A true KR20210096121A (ko) 2021-08-04

Family

ID=70460249

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217017005A Ceased KR20210096121A (ko) 2018-11-05 2019-11-05 님 추출물의 항당뇨 활성 및 유로리틴 a 및 b의 상승작용적 조합물

Country Status (10)

Country Link
US (1) US20200138892A1 (https=)
EP (1) EP3876968A4 (https=)
JP (1) JP2022536223A (https=)
KR (1) KR20210096121A (https=)
CN (1) CN113226347A (https=)
AU (1) AU2019377432A1 (https=)
BR (1) BR112021008725A2 (https=)
CA (1) CA3118926A1 (https=)
MX (1) MX2021005246A (https=)
WO (1) WO2020097014A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220098228A1 (en) * 2020-09-28 2022-03-31 Natreon, Inc. Methods and compositions for improving the immune system and providing immuno-protection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
JP2005325025A (ja) * 2004-05-12 2005-11-24 Green Kanpo Seiyaku Kk 糖尿病予防・治療組成物
WO2006030426A1 (en) * 2004-09-13 2006-03-23 Amcod Limited Herbal compositions for treatment of diabetes

Also Published As

Publication number Publication date
EP3876968A4 (en) 2022-09-14
WO2020097014A1 (en) 2020-05-14
US20200138892A1 (en) 2020-05-07
BR112021008725A2 (pt) 2021-08-03
CA3118926A1 (en) 2020-05-14
EP3876968A1 (en) 2021-09-15
AU2019377432A1 (en) 2021-06-10
JP2022536223A (ja) 2022-08-15
CN113226347A (zh) 2021-08-06
MX2021005246A (es) 2021-09-08

Similar Documents

Publication Publication Date Title
JP7069490B2 (ja) ユウリコマ・ロンギフォリア抽出物並びに免疫系の増強及び／又は刺激におけるその使用
Varnasseri et al. The effects of add-on therapy of Phyllanthus Emblica (Amla) on laboratory confirmed COVID-19 cases: a randomized, double-blind, controlled trial
US10166267B1 (en) Multi-component formulations for the treatment of cognitive decline including Alzheimer's disease
TWI678211B (zh) 管花肉蓯蓉萃取物及異類葉升麻苷於保護肌肉之用途
Majeed et al. Novel Emblica officinalis extract containing β-glucogallin vs. metformin: a randomized, open-label, comparative efficacy study in newly diagnosed type 2 diabetes mellitus patients with dyslipidemia
CN110267672A (zh) 用于预防或治疗炎性肠病的包含青黛提取物或其级分作为有效成分的药物组合物
KR20130019352A (ko) 꾸지뽕나무 줄기 추출물을 함유하는 아토피 질환 치료용 조성물
US20130261068A1 (en) Compositions and method for improving endothelial function and cardiovascular health
Sadino et al. An evidence-based review of Morinda citrifolia L.(Rubiaceae) fruits on animal models, human studies, and case reports
US10183047B2 (en) Chromium-containing compositions in combination with Phyllanthus emblica and shilajit having synergistic effects for improving endothelial function and cardiovascular health
KR20210096121A (ko) 님 추출물의 항당뇨 활성 및 유로리틴 a 및 b의 상승작용적 조합물
Khaled Effect of ascorbic acid, Balanites aegyptiaca, and strawberry supplementation on glycemic control and renal function biomarkers
US20160015740A1 (en) Chromium-containing compositions for improving endothelial function and cardiovascular health
Gupta et al. Nutraceuticals for diabetes and glucose balance
Nawaz et al. Evaluation of acute and repeated dose toxicity of the polyherbal formulation Linkus syrup in experimental animals
KR102763563B1 (ko) 반하, 복령, 후박, 자소엽 및 생강의 복합 추출물을 유효성분으로 포함하는 류마티스 관절염의 예방 또는 치료용 조성물
KR102900672B1 (ko) 호흡기 질환 예방 또는 치료용 복합 조성물
WO2016186695A1 (en) Synergistic compositions containing chromium with phyllanthus emblica and shilajit for improving endothelial function and cardiovascular health
Suresh et al. A review on the possible therapeutic intervention by herbal remedies on antipsychotic drugs induced metabolic disorder.
Oza Effect of Curcuma longa (turmeric) on postprandial glycemia in healthy, non-diabetic adults
KR102266256B1 (ko) 황기 추출물 및 지치 추출물을 유효성분으로 포함하는 항당뇨용 약학적 조성물
IMHONTU PREVENTIVE DIABETIC EFFECTS ON STREPTOZOCIN INDUCED DIABETIC RATS AFTER ADMINISTRATION OF BI-HERBAL MIXTURE OF Ocimum gratissimum AND Murraya koenigii
Alsurmi et al. The effect of Rosemary and Cinnamon extracts on blood glucose levels in albino rats with Alloxan-induced diabetes
WO2025037604A1 (ja) 脂肪分解及び／又は体重減少に対する内用組成物、有効性を判定する方法、並びに植物抽出物の品質の指標
BISHT et al. Methanol Extract of Barks of Anogeissus Latifolia: Appraisal of Antidiabetic Potential in D-Variant Encephalomyocarditis Virus-Induced Diabetes.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601